Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

Blood

Volumn 127, Issue 24, 2016, Pages 3035-3039

  Paiva, Bruno ^a   Martinez Lopez, Joaquin ^b   Corchete, Luis A ^c   Sanchez Vega, Beatriz ^b   Rapado, Inmaculada ^b   Puig, Noemi ^c   Barrio, Santiago ^b   Sanchez, Maria Luz ^d   Alignani, Diego ^a   Lasa, Marta ^a   De Coca, Alfonso García ^e   Pardal, Emilia ^f   Oriol, Alberto ^g   Garcia, Maria Esther Gonzalez ^h   Escalante, Fernando ⁱ   González López, Tomás J ^j   Palomera, Luis ^k   Alonso, José ^l   Prosper, Felipe ^a   Orfao, Alberto ^d   Vidriales, Maria Belen ^c   Mateos, María Victoria ^c   Lahuerta, Juan Jose ^b   Gutierrez, Norma C ^c   San Miguel, Jesús F ^a   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CSIC   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f HOSPITAL VIRGEN DEL PUERTO   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL DE CABUEÑES   (Spain)

ⁱ HOSPITAL DE LEÓN   (Spain)

^j HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^l HOSPITAL RÍO CARRIÓN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; IMMUNOGLOBULIN LIGHT CHAIN;

AL AMYLOIDOSIS; APOPTOSIS; ARTICLE; CDH1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; FAS GENE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLIPR1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RCAN GENE; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; WHOLE EXOME SEQUENCING; AMYLOIDOSIS; CELL CLONE; GENE EXPRESSION PROFILING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; IMMUNOPHENOTYPING; METABOLISM; MICROARRAY ANALYSIS; PARAPROTEINEMIA; PATHOLOGY;

AMYLOIDOSIS; CLONE CELLS; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOPHENOTYPING; MICROARRAY ANALYSIS; PARAPROTEINEMIAS; PHENOTYPE; PLASMA CELLS; TRANSCRIPTOME;

EID: 85017353202     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-673095     Document Type: Article

References (25)

1. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049-3058.
2. Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111(9):4700-4705.
3. Bochtler T, Hegenbart U, Kunz C, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014;21(1):9-17.
4. Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009;94(3):380-386.
5. Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 2002;117(2):427-435.
6. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001;98(7):2266-2268.
7. Warsame R, Kumar SK, Gertz MA, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015;5:e310.
8. Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371-1378.
9. Arendt BK, Ramirez-Alvarado M, Sikkink LA, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008;112(5):1931-1941.
10. Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005;105(2):794-803.
11. Paiva B, Vídriales MB, Pérez JJ, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood. 2011;117(13):3613-3616.
12. Paiva B, Corchete LA, Vidriales MB, et al. The cellular origin and malignant transformation of Waldenström macroglobulinemia. Blood. 2015;125(15):2370-2380.
13. López-Corral L, Sarasquete ME, Beà S,etal. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012;26(12):2521-2529.
14. Cho MH, Park JH, Choi HJ, et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun. 2015;6:7821.
15. Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015;17:6-014-0506-7.
16. Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31(7):868-875.
17. Li L, Ren C, Yang G, et al. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011;71(24):7694-7704.
18. Martínez-Høyer S, Solé-Sánchez S, Aguado F, et al. A novel role for an RCAN3-derived peptide as a tumor suppressor in breast cancer. Carcinogenesis. 2015;36(7):792-799.
19. Yu F, Xie D, Ng SS, et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 2015;368(1):135-143.
20. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003;102(13):4504-4511.
21. Bochtler T, Hegenbart U, Heiss C, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood. 2011;117(14):3809-3815.
22. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826-833.
23. Weinhold N, Försti A, da Silva Filho MI, et al. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia. 2014;28(11):2254-2256.
24. Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
25. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911-3920.